Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation
Eli Lilly (NYSE: LLY) announced plans to invest up to $250 million in an expanded collaboration with Purdue University over the next eight years, potentially becoming the largest industry-academic agreement in U.S. history. The Lilly-Purdue 360 Initiative, extending through 2032, aims to accelerate pharmaceutical innovation across the entire pipeline.
The partnership will focus on key areas including: AI-powered drug discovery, technology-enabled treatment acceleration, manufacturing optimization through robotics and AI, and workforce development. The collaboration includes on-site research opportunities at both institutions and builds on existing programs like Lilly Scholars and the Lilly and Purdue Research Alliance Center (LPRC).
Eli Lilly (NYSE: LLY) ha annunciato l'intenzione di investire fino a 250 milioni di dollari in una collaborazione ampliata con la Purdue University nei prossimi otto anni, potenzialmente diventando il più grande accordo tra industria e mondo accademico nella storia degli Stati Uniti. L'iniziativa Lilly-Purdue 360, che si estenderà fino al 2032, mira ad accelerare l'innovazione farmaceutica lungo l'intero processo di sviluppo.
La partnership si concentrerà su aree chiave quali: scoperta di farmaci supportata dall'intelligenza artificiale, accelerazione dei trattamenti tramite tecnologie avanzate, ottimizzazione della produzione con robotica e AI, e sviluppo delle competenze della forza lavoro. La collaborazione prevede opportunità di ricerca in loco presso entrambe le istituzioni e si basa su programmi già esistenti come Lilly Scholars e il Lilly and Purdue Research Alliance Center (LPRC).
Eli Lilly (NYSE: LLY) anunció planes para invertir hasta 250 millones de dólares en una colaboración ampliada con la Universidad de Purdue durante los próximos ocho años, convirtiéndose potencialmente en el acuerdo más grande entre la industria y el ámbito académico en la historia de Estados Unidos. La iniciativa Lilly-Purdue 360, que se extenderá hasta 2032, tiene como objetivo acelerar la innovación farmacéutica en toda la cadena de desarrollo.
La asociación se centrará en áreas clave como: descubrimiento de fármacos impulsado por inteligencia artificial, aceleración de tratamientos mediante tecnología, optimización de la fabricación con robótica e IA, y desarrollo del talento laboral. La colaboración incluye oportunidades de investigación en sitio en ambas instituciones y se basa en programas existentes como Lilly Scholars y el Lilly and Purdue Research Alliance Center (LPRC).
Eli Lilly (NYSE: LLY)는 향후 8년간 퍼듀 대학교와의 협력을 확대하여 최대 2억 5천만 달러를 투자할 계획을 발표했으며, 이는 미국 역사상 가장 큰 산업-학계 협약이 될 가능성이 있습니다. 2032년까지 이어질 Lilly-Purdue 360 이니셔티브는 전체 제약 개발 과정을 가속화하는 것을 목표로 합니다.
이 파트너십은 핵심 분야에 중점을 두는데, 인공지능 기반 신약 발견, 기술을 활용한 치료 가속화, 로봇공학 및 AI를 통한 제조 최적화, 그리고 인력 개발이 포함됩니다. 양 기관 현장 연구 기회를 제공하며, Lilly Scholars 및 Lilly and Purdue Research Alliance Center(LPRC)와 같은 기존 프로그램을 기반으로 합니다.
Eli Lilly (NYSE : LLY) a annoncé son intention d'investir jusqu'à 250 millions de dollars dans une collaboration élargie avec l'Université Purdue au cours des huit prochaines années, ce qui pourrait devenir le plus grand accord industrie-université de l'histoire des États-Unis. L'initiative Lilly-Purdue 360, qui s'étendra jusqu'en 2032, vise à accélérer l'innovation pharmaceutique tout au long de la chaîne de développement.
Le partenariat se concentrera sur des domaines clés tels que : la découverte de médicaments assistée par intelligence artificielle, l'accélération des traitements grâce à la technologie, l'optimisation de la fabrication via la robotique et l'IA, ainsi que le développement des compétences des travailleurs. La collaboration inclut des opportunités de recherche sur site dans les deux institutions et s'appuie sur des programmes existants comme Lilly Scholars et le Lilly and Purdue Research Alliance Center (LPRC).
Eli Lilly (NYSE: LLY) kündigte Pläne an, in den nächsten acht Jahren bis zu 250 Millionen US-Dollar in eine erweiterte Zusammenarbeit mit der Purdue University zu investieren, was möglicherweise die größte Industrie-Akademie-Vereinbarung in der Geschichte der USA darstellt. Die Lilly-Purdue 360 Initiative, die bis 2032 läuft, zielt darauf ab, die pharmazeutische Innovation über die gesamte Pipeline hinweg zu beschleunigen.
Die Partnerschaft konzentriert sich auf Schlüsselbereiche wie KI-gestützte Wirkstoffentdeckung, technologiegestützte Beschleunigung von Behandlungen, Optimierung der Herstellung durch Robotik und KI sowie Entwicklung der Arbeitskräfte. Die Zusammenarbeit umfasst Forschungsgelegenheiten vor Ort an beiden Institutionen und baut auf bestehenden Programmen wie Lilly Scholars und dem Lilly and Purdue Research Alliance Center (LPRC) auf.
- Significant $250 million investment over 8 years strengthens R&D capabilities
- Integration of AI and advanced technologies could accelerate drug development and manufacturing processes
- Enhanced workforce development program ensures talent pipeline for future growth
- Extended partnership through 2032 provides long-term research stability
- Large financial commitment might impact short-term capital allocation
- Long-term nature of academic research may delay immediate returns on investment
Insights
Lilly's $250M Purdue partnership expands R&D capabilities, enhances AI/ML drug discovery, and builds competitive advantage in pharmaceutical innovation.
Eli Lilly's planned
The initiative's focus on AI-powered drug discovery tools and machine learning applications will likely accelerate Lilly's early-stage pipeline, potentially reducing both the time and cost of identifying viable drug candidates. This investment in computational drug discovery aligns with industry-wide shifts toward technology-enabled research methodologies that can identify novel targets and compounds more efficiently than traditional approaches.
Most significantly, the collaboration targets the critical "valley of death" gap between laboratory discoveries and clinical applications - a notorious bottleneck in pharmaceutical development where promising compounds often fail to advance. By facilitating technology-enabled approaches to accelerate treatments from Phase I studies through regulatory approval, Lilly is strategically addressing one of the industry's most persistent challenges.
The manufacturing innovation elements focusing on robotics, AI, and data sciences to quickly scale production capacity address another key competitive advantage - the ability to rapidly commercialize successful compounds. In an industry where manufacturing complexity often creates significant barriers to market entry, these advancements could substantially enhance Lilly's operational efficiency and reduce time-to-market for new therapies.
The strategic workforce development component ensures Lilly maintains access to specialized talent in an increasingly competitive labor market for pharmaceutical expertise. By establishing physical research presence at Purdue while bringing university researchers into Lilly facilities, the company creates a powerful talent pipeline that competitors will struggle to replicate.
The Lilly-Purdue 360 Initiative aims to achieve several key goals, including discovering and accelerating the delivery of medicines to patients; bridging the gap between laboratory discoveries and clinical applications; creating more resilient, efficient and sustainable supply chains; and deploying innovative, scalable approaches to workforce development. The expanded collaboration is also expected to generate significant economic benefits for
The earlier agreement, which had been set to expire in 2027, will now extend with four new projects added through 2032. Additionally, it will engage existing joint programs, such as Lilly Scholars at Purdue and the Lilly and Purdue Research Alliance Center (LPRC). Purdue will make space available for Lilly researchers on-site in
"As potentially the largest single university-industry research agreement in American history, Lilly and Purdue are blazing a new trail to the endless frontier," said Purdue University President Mung Chiang. "As for our state, when its largest company and the largest university expand collaboration at a scale never seen before, especially in the backdrop of Lilly's manufacturing facility in LEAP, today marks a monumental watershed in the generation of jobs, workforce, and innovation along America's Hard-Tech Corridor. We thank Lilly for its pioneering impact on health and medicine in our society and for what is now the largest single research funding, from public or private capital, in Purdue's history."
To achieve the initiative's ambitious goals, Lilly and Purdue will concentrate on several key areas:
- Applying AI-powered tools to augment traditional drug discovery methods while leveraging advancements in machine learning and big data analytics to explore disease mechanisms and personalized treatments
- Facilitating technology-enabled approaches to accelerate potential treatments from Phase I clinical studies to regulatory approval and technology transfer into manufacturing — critical focus areas of the Lilly Medicine Foundry
- Incorporating robotics, AI, and data sciences to quickly scale manufacturing capacity more effectively, with improved compliance and greater sustainability
- Enhancing workforce development to ensure a strong talent pipeline to meet the demands of Lilly and other
Indiana employers
"Accelerating the delivery of life-changing medicines demands a highly skilled workforce and continuous innovation across discovery, process development and manufacturing," said David A. Ricks, Lilly's chair and CEO. "Through this expanded collaboration with Purdue, we look forward to combining our strengths in advanced technologies and cutting-edge science to pioneer new methods of delivering next-generation medicines to advance human health."
The Lilly-Purdue 360 Initiative supports Purdue's One Health initiative, which advances knowledge and innovation related to animal, human, and plant well-being through novel interdisciplinary initiatives and partnerships with industry.
About Purdue University
Purdue University is a public research university leading with excellence at scale. Ranked among top 10 public universities in
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. C-LLY
Refer to: | Carla Cox; cox_carla@lilly.com; 317-750-3923 (Media) |
Michael Czapar; czapar_michael_c@lilly.com; 317-617-0983 (Investors) | |
Trevor Peters; 317-989-1151; peter237@purdue.edu (Media) |
View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-plans-to-expand-purdue-university-collaboration-with-up-to-a-250-million-investment-to-accelerate-pharmaceutical-innovation-302451055.html
SOURCE Eli Lilly and Company
FAQ
What is the value and duration of Eli Lilly's (LLY) investment in Purdue University?
What are the main focus areas of the Lilly-Purdue 360 Initiative?
How will the LLY-Purdue collaboration benefit Indiana's economy?
What existing programs are included in the expanded Eli Lilly-Purdue partnership?
Where will the collaborative research between Lilly and Purdue take place?
